PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation

Autologous stem cell transplantation (ASCT) remains the standard of care for patients with relapsed/refractory (RR) classical Hodgkin lymphoma (cHL) who respond to salvage chemotherapy. However, relapse after ASCT remains a frequent cause of treatment failure, with poor subsequent prognosis. Because...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Armand, Philippe, Chen, Yi-Bin, Redd, Robert A., Joyce, Robin M., Bsat, Jad, Jeter, Erin, Merryman, Reid W., Coleman, Kimberly C., Dahi, Parastoo B., Nieto, Yago, LaCasce, Ann S., Fisher, David C., Ng, Samuel Y., Odejide, Oreofe O., Freedman, Arnold S., Kim, Austin I., Crombie, Jennifer L., Jacobson, Caron A., Jacobsen, Eric D., Wong, Jeffrey L., Patel, Sanjay S., Ritz, Jerome, Rodig, Scott J., Shipp, Margaret A., Herrera, Alex F.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2019
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6609955/
https://ncbi.nlm.nih.gov/pubmed/30952672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000215
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak